These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23155046)

  • 1. Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.
    Fjellström O; Deinum J; Sjögren T; Johansson C; Geschwindner S; Nerme V; Legnehed A; McPheat J; Olsson K; Bodin C; Paunovic A; Gustafsson D
    J Biol Chem; 2013 Jan; 288(2):873-85. PubMed ID: 23155046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
    Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA
    Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serpin latency transition at atomic resolution.
    Cazzolli G; Wang F; a Beccara S; Gershenson A; Faccioli P; Wintrode PL
    Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15414-9. PubMed ID: 25313058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
    J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a small molecule PAI-1 inhibitor, ZK4044.
    Liang A; Wu F; Tran K; Jones SW; Deng G; Ye B; Zhao Z; Snider RM; Dole WP; Morser J; Wu Q
    Thromb Res; 2005; 115(4):341-50. PubMed ID: 15668194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function.
    Gorlatova NV; Elokdah H; Fan K; Crandall DL; Lawrence DA
    J Biol Chem; 2003 May; 278(18):16329-35. PubMed ID: 12606560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor.
    Gorlatova NV; Cale JM; Elokdah H; Li D; Fan K; Warnock M; Crandall DL; Lawrence DA
    J Biol Chem; 2007 Mar; 282(12):9288-96. PubMed ID: 17276980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein conformational change delayed by steric hindrance from an N-linked glycan.
    Bager R; Johansen JS; Jensen JK; Stensballe A; Jendroszek A; Buxbom L; Sørensen HP; Andreasen PA
    J Mol Biol; 2013 Aug; 425(16):2867-77. PubMed ID: 23702291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms.
    Sancho E; Declerck PJ; Price NC; Kelly SM; Booth NA
    Biochemistry; 1995 Jan; 34(3):1064-9. PubMed ID: 7827021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C.
    Dupont DM; Blouse GE; Hansen M; Mathiasen L; Kjelgaard S; Jensen JK; Christensen A; Gils A; Declerck PJ; Andreasen PA; Wind T
    J Biol Chem; 2006 Nov; 281(47):36071-81. PubMed ID: 17018527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetically controlled folding of the serpin plasminogen activator inhibitor 1.
    Wang Z; Mottonen J; Goldsmith EJ
    Biochemistry; 1996 Dec; 35(51):16443-8. PubMed ID: 8987976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes.
    Thompson LC; Goswami S; Peterson CB
    Protein Sci; 2011 Feb; 20(2):366-78. PubMed ID: 21280128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity.
    Jankun J; Specht Z; Szkudlarek M; Greenfield R; Gaikwad B; Trifonov L; Vaugeois J; Aleem AM; Basrur V; Selman SH; Zavodszky MI; Skrzypczak-Jankun E
    Int J Mol Med; 2006 Mar; 17(3):437-47. PubMed ID: 16465390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-reporter high-throughput screen for small-molecule
    Reinke AA; Li SH; Warnock M; Shaydakov ME; Guntaka NS; Su EJ; Diaz JA; Emal CD; Lawrence DA
    J Biol Chem; 2019 Feb; 294(5):1464-1477. PubMed ID: 30510136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
    Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
    Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator.
    Björquist P; Ehnebom J; Inghardt T; Deinum J
    Biochim Biophys Acta; 1997 Aug; 1341(1):87-98. PubMed ID: 9300812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.